5 minute read
May 13, 2022
JBJ-09-063: An Oral Allosteric Mutant EGFR L858R Inhibitor
JBJ-09-063
allosteric mutant-EGFR inhibitor in vivo efficacy in osimertinib-resistant xenograft models from opt. of prev. disclosed EGFR inhibitor Nat. Cancer Dana-Farber Cancer Institute, Boston, MA
Reviewer:
Loading...
